1Gaine SP, Rubin LJ (1998) Primary pulmonary hypertension. LancetM 352: 719-725.

2Chin KM, Rubin LJ (2008) Pulmonary arterial hypertension. J Am Coll Cardiol 51: 1527- 1538.

3Rich S, Dantzker DR, Ayres SM, Bergofsky EH, Brundage BH, Detre KM, et al. (1987) Primary pulmonary hypertension. A national prospective study. Ann Intern Med 107: 216-223.

4Strange G, Gabbay E, Kermeen F, Williams T, Carrington M, Stewart S, et al. (2013) Time from symptoms to definitive diagnosis of idiopathic pulmonary arterial hypertension: The delay study. Pulm Circ 3: 89-94.

5Vachiery JL, Gaine S (2012) Challenges in the diagnosis and treatment of pulmonary arterial hypertension. Eur Respir Rev 21: 313-320.

6Frost AE, Badesch DB, Barst RJ, Benza RL, Elliott CG, Farber HW, et al. (2011) The changing picture of patients with pulmonary arterial hypertension in the United States: how REVEAL differs from historic and non-US Contemporary Registries. Chest 139: 128-137.

7Humbert M, Sitbon O, Chaouat A, Bertocchi M, Habib G, Gressin V, et al. (2010) Survival in patients with idiopathic, familial, and anorexigen-associated pulmonary arterial hypertension in the modern management era. Circulation 122: 156-63.

8Humbert M, Sitbon O, Chaouat A, Bertocchi M, Habib G, Gressin V, et al. (2006) Pulmonary arterial hypertension in France: results from a national registry. Am J Respir Crit Care Med. 173: 1023-1030.

9Peacock AJ, Naeije R, Galie N, Rubin L (2009) End-points and clinical trial design in pulmonary arterial hypertension: have we made progress? Eur Respir J 34: 231-242.

10Frost AE, Langleben D, Oudiz R, Hill N, Horn E, McLaughlin V, et al. (2005) The 6-min walk test (6MW) as an efficacy endpoint in pulmonary arterial hypertension clinical trials: demonstration of a ceiling effect. Vascul Pharmacol. 2005;43: 36-39.

11Galie N, Rubin L, Hoeper M, Jansa P, Al-Hiti H, Meyer G, et al. (2008) Treatment of patients with mildly symptomatic pulmonary arterial hypertension with bosentan (EARLY study): a double-blind, randomized controlled trial. Lancet 371: 2093-100.

12Peacock A, Keogh A, Humbert M (2010) Endpoints in pulmonary arterial hypertension: the role of clinical worsening. Curr Opin Pulm Med 16 Suppl 1:S1-9.

13Halpern SD, Taichman DB (2009) Misclassification of pulmonary hypertension due to reliance on pulmonary capillary wedge pressure rather than left ventricular end-diastolic pressure. Chest 136: 37-43.

14Brown LM, Chen H, Halpern S, Taichman D, McGoon MD, Farber HW, et al. (2011) Delay in recognition of pulmonary arterial hypertension: factors identified from the REVEAL Registry. Chest 140: 19-26.

15Palevsky HI (2011) The early diagnosis of pulmonary arterial hypertension: can we do better? Chest. 140: 4-6.

16Tolle JJ, Waxman AB, Van Horn TL, Pappagianopoulos PP, Systrom DM (2008) Exercise-induced pulmonary arterial hypertension. Circulation 118: 2183-2189.

17Woods PR, Frantz RP, Taylor BJ, Olson TP, Johnson BD (2011) The usefulness of submaximal exercise gas exchange to define pulmonary arterial hypertension. J Heart Lung Transplant 30: 1133-1142.

18Snyder EM, Johnson BD, Beck KC (2005) An open-circuit method for determining lung diffusing capacity during exercise: comparison to rebreathe. J Appl Physiol. 99: 1985-1991.

19Tamhane RM, Johnson RL, Jr., Hsia CC (2001) Pulmonary membrane diffusing capacity and capillary blood volume measured during exercise from nitric oxide uptake. Chest 120:1850-1856.

20Hsia CC, McBrayer DG, Ramanathan M (1995) Reference values of pulmonary diffusing capacity during exercise by a rebreathing technique. Am J Respir Crit Care Med. 152: 658-665.

21Chandra S, Shah SJ, Thenappan T, Archer SL, Rich S, Gomberg-Maitland M (2010) Carbon monoxide diffusing capacity and mortality in pulmonary arterial hypertension. J Heart Lung Transplant 29: 181-187.

22Hsia CC (2002) Recruitment of lung diffusing capacity: update of concept and application. Chest. 122:1774-1783.

23Charloux A, Enache I, Richard R, Oswald-Mammosser M, Lonsdorfer-Wolf E, Piquard F, et al. (2010) Diffusing capacity of the lung for CO and pulmonary blood flow during incremental and intermittent exercise. Scand J Med Sci Sports 20: e121-129.

24Johnson RL, Jr., Spicer WS, Bishop JM, Forster RE (1960) Pulmonary capillary blood volume, flow and diffusing capacity during exercise. J Appl Physiol. 15: 893-902.

25Borg GA (1982) Psychophysical bases of perceived exertion. Med Sci Sports Exerc. 14: 377-381.

26Borg GAV (1982) A category scale with ratio properties for intermodal and interindividual comparisons. In: Geissler H, Pezold P, editors. Psychophysical Judgement and the Process of Perception. Berlin: Veb Deutsche Verlag Wissen Schaften 25-34.

27Hsia CC, Herazo LF, Ramanathan M, Johnson RL, Jr. (1995) Cardiac output during exercise measured by acetylene rebreathing, thermodilution, and Fick techniques. J Appl Physiol. 78: 1612-1616.

28Wheatley CM, Baker SE, Taylor BJ, Keller-Ross ML, Chase SC, Carlson AR, et al. (2017) Influence of Inhaled Amiloride on Lung Fluid Clearance in Response to Normobaric Hypoxia in Healthy Individuals. High Alt Med Biol.

29Wheatley CM, Baker SE, Morgan MA, Martinez MG, Morgan WJ, Wong EC, et al. (2015) Effects of exercise intensity compared to albuterol in individuals with cystic fibrosis. Respir Medb 109: 463-474.

30Johnson BD, Beck KC, Proctor DN, Miller J, Dietz NM, Joyner MJ (2000) Cardiac output during exercise by the open circuit acetylene washing method: comparison with direct Fick. J Appl Physiol. 88: 1650-1658.

31Liu Y, Menold E, Dullenkopf A, Reissnecker S, Lormes W, Lehmann M, et al. (1997) Validation of the acetylene rebreathing method for measurement of cardiac output at rest and during high- intensity exercise. Clin Physiol 17: 171-182.

32Hoeper MM, Maier R, Tongers J, Niedermeyer J, Hohlfeld JM, Hamm M, et al. (1999) Determination of cardiac output by the Fick method, thermodilution, and acetylene rebreathing in pulmonary hypertension. Am J Respir Crit Care Med 160: 535-541.

33Taylor BJ, Olson TP, Chul Ho K, Maccarter D, Johnson BD (2013) Use of noninvasive gas exchange to track pulmonary vascular responses to exercise in heart failure. Clin Med Insights Circ Respir Pulm Med 7: 53-60.

34Hansen JE, Ulubay G, Chow BF, Sun XG, Wasserman K (2007) Mixed-expired, and end-tidal CO2 distinguish between ventilation and perfusion defects during exercise testing in patients with lung and heart diseases. Chest 132: 977-983.

35Olson LJ, Snyder EM, Beck KC, Johnson BD (2006) Reduced rate of alveolar-capillary recruitment and fall of pulmonary diffusing capacity during exercise in patients with heart failure. J Card Fail 12: 299-306.

36Hughes JM, Lockwood DN, Jones HA, Clark RJ (1991) DLCO/Q and diffusion limitation at rest and on exercise in patients with interstitial fibrosis. Respir Physiol 83: 155-66.

37Hsia CC, Ramanathan M, Estrera AS (1992) Recruitment of diffusing capacity with exercise in patients after pneumonectomy. Am Rev Respir Dis 145: 811-6.

38Sun XG, Hansen JE, Oudiz RJ, Wasserman K (2001) Exercise pathophysiology in patients with primary pulmonary hypertension. Circulation. 104: 429-435.

39Deboeck G, Niset G, Lamotte M, Vachiery JL, Naeije R (2004) Exercise testing in pulmonary arterial hypertension and in chronic heart failure. Eur Respir J. 23: 747-751.

40Badano LP, Ginghina C, Easaw J, Muraru D, Grillo MT, Lancellotti P, et al. (2010) Right ventricle in pulmonary arterial hypertension: hemodynamics, structural changes, imaging, and proposal of a study protocol aimed to assess remodeling and treatment effects. European journal of echocardiography: the journal of the Working Group on Echocardiography of the European Society of Cardiology 11: 27-37.

41Woods PR, Taylor BJ, Frantz RP, Johnson BD (2012) A pulmonary hypertension gas exchange severity (PH-GXS) score to assist with the assessment and monitoring of pulmonary arterial hypertension. Am J Cardiol. 109: 1066-1072.

42Galie N, Corris PA, Frost A, Girgis RE, Granton J, Jing ZC, et al. (2013) Updated treatment algorithm of pulmonary arterial hypertension. J Am Coll Cardiol 62: D60-72.

43McLaughlin VV, Oudiz RJ, Frost A, Tapson VF, Murali S, Channick RN, et al. (2006) Randomized study of adding inhaled iloprost to existing bosentan in pulmonary arterial hypertension. Am J Respir Crit Care Med 174: 1257-1263.

44Sitbon O, Jais X, Savale L, Cottin V, Bergot E, Macari EA, et al. (2014) Upfront triple combination therapy in pulmonary arterial hypertension: a pilot study. Eur Respir J 43: 1691- 1697.

45Humbert M, Barst RJ, Robbins IM, Channick RN, Galie N, Boonstra A, et al.(2004) Combination of bosentan with epoprostenol in pulmonary arterial hypertension: BREATHE-2 Eur Respir J 24: 353-359.

46Galie N, Barbera JA, Frost AE, Ghofrani HA, Hoeper MM, McLaughlin VV, et al. (2015) Initial Use of Ambrisentan plus Tadalafil in Pulmonary Arterial Hypertension N Engl J Med 373: 834-844.

47McLaughlin VV, Benza RL, Rubin LJ, Channick RN, Voswinckel R, Tapson VF, et al. (2010) Addition of inhaled treprostinil to oral therapy for pulmonary arterial hypertension: a randomized controlled clinical trial. J Am Coll Cardiol 55: 1915-1922.

48Pan J, Lei L, Zhao C (2018) Comparison between the efficacy of combination therapy and monotherapy in connective tissue disease-associated pulmonary arterial hypertension: a systematic review and meta-analysis. Clin Exp Rheumatol 36: 1095- 1102.

49Lajoie AC, Lauziere G, Lega JC, Lacasse Y, Martin S, Simard S, et al. (2016) Combination therapy versus monotherapy for pulmonary arterial hypertension: a meta-analysis Lancet 4: 291-305.

50Galie N, Palazzini M, Manes A (2010) Pulmonary arterial hypertension: from the kingdom of the near-dead to multiple clinical trial meta-analyses. Eur Heart J 31: 2080-2086.

51Ghofrani HA, Humbert M (2014) The role of combination therapy in managing pulmonary arterial hypertension. Eur Respir Rev 23: 469-475.

52Woods PR, Frantz RP, Johnson BD (2010) The usefulness of submaximal exercise gas exchange in pulmonary arterial hypertension: a case series. Clin Med Insights Circ Respir Pulm Med 4: 35-40.